Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852444 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAGAAL3MBTL1THRB | |
| SCHEMBL744044 | 0.87 | TBXAS1 (0.48) | SMN1; SMN2LMNAL3MBTL1CFTRSLC6A2 | |
| SCHEMBL29931638 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAGAAL3MBTL1THRB | |
| SCHEMBL2436131 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAGAAL3MBTL1THRB | |
| SCHEMBL25287082 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAGAAL3MBTL1HTT | |
| SCHEMBL31038319 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAGAAL3MBTL1HTT | |
| Pyridine SCHEMBL8587529 | 0.84 | LMNA (0.60) | SMN1; SMN2LMNAGAATHRBHTT | |
| SCHEMBL8461393 | 0.84 | TBXAS1 (0.49) | SMN1; SMN2LMNAL3MBTL1CFTRSLC6A2 | |
| SCHEMBL4779810 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAGAAL3MBTL1HTT | |
| SCHEMBL4775271 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAGAAL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314945-B1 | ELECTROCHROMIC ELEMENT, ELECTROCHROMIC DISPLAY DEVICE, ELECTROCHROMIC LIGHT-CONTROLLING DEVICE, AND ELECTROLYTE COMPOSITION | RICOH CO LTD (JP) | 2025-12-17 | — | — | EP | claimed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-06-18 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4204399-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS Therapy Development Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4632925-A | INSULIN LOWERING ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0068880-B1 | PHOTOGRAPHIC ELEMENTS CAPABLE OF PROVIDING OXOINDOLIZINE AND OXOINDOLIZINIUM DYE COMPOUNDS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-08-07 | — | — | EP | disclosed |
| EP-0068876-B1 | OXOINDOLIZINE AND OXOINDOLIZINIUM DYES AND PROCESSES FOR THEIR PREPARATION | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-04-03 | — | — | EP | disclosed |
| EP-0088128-A4 | ANTIINFLAMMATORY AND ANALGETIC 4-PYRIDYLPYRIDAZIN(2H)-3-ONES. | DIAMOND SHAMROCK CORP (US) | 1984-04-06 | — | — | EP | disclosed |
| US-4433152-A | ANTIINFLAMMATORY AGENT, ANTIALLERGEN OR ANTICOAGULANT | NIPPON CHEMIPHAR CO., LTD. (JP) | 1984-02-21 | — | — | US | disclosed |
| EP-0088128-A1 | ANTIINFLAMMATORY AND ANALGETIC 4-PYRIDYLPYRIDAZIN(2H)-3-ONES | DIAMOND SHAMROCK CORPORATION (US) | 1983-09-14 | — | — | EP | disclosed |
| WO-1983000863-A1 | ANTIINFLAMMATORY AND ANALGETIC 4-PYRIDYLPYRIDAZIN(2H)-3-ONES | DIAMOND SHAMROCK CORP (US) | 1983-03-17 | — | — | WO | disclosed |
| EP-0068876-A1 | Oxoindolizine and oxoindolizinium dyes and processes for their preparation | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | SOD1, SMN1; SMN2, CLN6 | SMN1; SMN2 2/4885LMNA 1550/4885GAA 50/4885 |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | SMN1; SMN2 2/4885LMNA 1550/4885GAA 50/4885 |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | SMN1; SMN2 4392/4885LMNA 4245/4885GAA 4039/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | SMN1; SMN2 2485/4885LMNA 3240/4885GAA 1341/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | SMN1; SMN2 2/4885LMNA 1550/4885GAA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.